QCG
RVMD icon

Quadrant Capital Group’s Revolution Medicines RVMD Stock Holding History

Quadrant Capital Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,312
Closed -$128K – 2301
2026
Q1 		$128K Hold
1,312
– – ﹤0.01% 1412
2025
Q4 		$105K Buy
1,312
+995
+314% +$65.2K ﹤0.01% 1479
2025
Q3 		$14.8K Buy
+317
New +$12.4K ﹤0.01% 2044
2025
Q2 		– Sell
-322
Closed -$11.4K – 2350
2025
Q1 		$11.4K Sell
322
-19
-6% -$771 ﹤0.01% 2194
2024
Q4 		$14.9K Hold
341
– – ﹤0.01% 1998
2024
Q3 		$15.5K Sell
341
-37
-10% -$1.61K ﹤0.01% 1996
2024
Q2 		$14.7K Hold
378
– – ﹤0.01% 1982
2024
Q1 		$12.2K Hold
378
– – ﹤0.01% 2032
2023
Q4 		$10.8K Hold
378
– – ﹤0.01% 2039
2023
Q3 		$10.5K Hold
378
– – ﹤0.01% 1974
2023
Q2 		$10.1K Hold
378
– – ﹤0.01% 1988
2023
Q1 		$8.19K Buy
+378
New +$9.31K ﹤0.01% 2108
2022
Q4 		– Sell
-73
Closed -$1K – 2835
2022
Q3 		$1K Buy
+73
New +$1.6K ﹤0.01% 2553

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Quadrant Capital Group's RVMD Position: Q2 2026 in Review

Quadrant Capital Group sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 1,312 shares — an estimated $128K sold.

Quadrant Capital Group first reported a position in RVMD in Q3 2022 and held it in 13 quarters. The position peaked at $128K in Q1 2026. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Quadrant Capital Group reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,312 Revolution Medicines shares in Q2 2026, an estimated $128K.
  • Quadrant Capital Group first reported a position in Revolution Medicines in Q3 2022 and held it in 13 quarters.
  • Quadrant Capital Group's Revolution Medicines position peaked at $128K in Q1 2026.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.